DE69737415D1 - Gespannte, helixformende peptide und verfahren um sie herzustellen - Google Patents

Gespannte, helixformende peptide und verfahren um sie herzustellen

Info

Publication number
DE69737415D1
DE69737415D1 DE69737415T DE69737415T DE69737415D1 DE 69737415 D1 DE69737415 D1 DE 69737415D1 DE 69737415 T DE69737415 T DE 69737415T DE 69737415 T DE69737415 T DE 69737415T DE 69737415 D1 DE69737415 D1 DE 69737415D1
Authority
DE
Germany
Prior art keywords
methods
helix
tightened
create
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69737415T
Other languages
English (en)
Other versions
DE69737415T2 (de
Inventor
Andrew Braisted
J Kevin Judice
Robert S Mcdowell
J Christopher Phelan
Melissa A Starovasnik
James A Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69737415D1 publication Critical patent/DE69737415D1/de
Application granted granted Critical
Publication of DE69737415T2 publication Critical patent/DE69737415T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69737415T 1996-11-06 1997-11-05 Gespannte, helixformende peptide und verfahren um sie herzustellen Expired - Fee Related DE69737415T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74369896A 1996-11-06 1996-11-06
US743698 1996-11-06
US87669897A 1997-06-16 1997-06-16
US876698 1997-06-16
PCT/US1997/020069 WO1998020036A1 (en) 1996-11-06 1997-11-05 Constrained helical peptides and methods of making same

Publications (2)

Publication Number Publication Date
DE69737415D1 true DE69737415D1 (de) 2007-04-12
DE69737415T2 DE69737415T2 (de) 2007-10-31

Family

ID=27114189

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737415T Expired - Fee Related DE69737415T2 (de) 1996-11-06 1997-11-05 Gespannte, helixformende peptide und verfahren um sie herzustellen

Country Status (8)

Country Link
EP (1) EP0938497B1 (de)
JP (1) JP2001503064A (de)
AT (1) ATE355300T1 (de)
AU (1) AU745101B2 (de)
CA (1) CA2270869A1 (de)
DE (1) DE69737415T2 (de)
IL (1) IL129772A0 (de)
WO (1) WO1998020036A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
JP2002522029A (ja) 1998-07-27 2002-07-23 ジェネンテック・インコーポレーテッド コートタンパク質の改変によるファージ提示における改良した形質転換効率
JP3971108B2 (ja) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
EP1282437B1 (de) 2000-05-16 2008-03-19 Genentech, Inc. Behandlung von knorpelerkrankungen
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
MXPA03011985A (es) 2001-06-20 2004-03-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
EP2067472A1 (de) 2002-01-02 2009-06-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
JP4667868B2 (ja) * 2002-08-06 2011-04-13 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 結合分子
ATE401345T1 (de) * 2002-08-06 2008-08-15 Aplagen Gmbh Synthetische mimetika von physiologischen bindungsmolekülen
EP1445614A1 (de) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verfahren zur in vitro Überwachung der Entwicklung von HIV Virus eines Individuums
FR2851165A1 (fr) * 2003-02-19 2004-08-20 Aventis Pasteur Antigene derivant de l'helice c de la proteine gp41
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
CA2548483A1 (en) * 2003-08-26 2005-03-10 Uwe Fiebig Induction of antiviral neutralizing antibodies in humans and animals
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
EP2161283B1 (de) 2003-11-17 2014-06-04 Genentech, Inc. Zusammensetzungen, die Antikörper gegen CD79b enthalten, die an Wachstumshemmer oder an zytotoxische Subtanzen gekoppelt sind und Verfahren zur Behandlung von Tumoren hämatopoetischen Ursprungs
BRPI0607985A2 (pt) 2005-03-10 2009-10-27 Genentech Inc modulador da dscr1, métodos de tratamento, método de melhoria de efeitos colaterais e método de inibição do crescimento de tumores
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2057465A4 (de) 2006-08-09 2010-04-21 Homestead Clinical Corp Organspezifische proteine und anwendungsverfahren dafür
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
ES2379413T3 (es) 2007-02-22 2012-04-25 Genentech, Inc. Procedimientos para detectar la enfermedad inflamatoria del intestino
CA2713089C (en) 2008-01-23 2017-11-21 Dana Farber Cancer Institute Compositions and methods for the treatment of viral infections
EP2319869B1 (de) 2008-06-20 2016-08-17 National University Corporation Okayama University ANTIKÖRPER GEGEN DEN OXIDIERTES LDL/ß²GPI-KOMPLEX UND ANWENDUNG DAVON
EP2324049B1 (de) * 2008-08-04 2016-05-25 The Government of the U.S.A. as represented by The Secretary of the dept. of Health & Human Services In der lipidschicht eines virusähnlichen partikelimpfstoffes verankerte proximale membranregion von hiv gp41
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
EP2442829B1 (de) * 2009-06-18 2021-02-24 Dana-Farber Cancer Institute, Inc. Strukturierte viralpeptidzusammensetzungen und verwendungsverfahren dafür
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
CA2781887C (en) 2009-11-30 2018-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2787657A1 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BR112012028010A2 (pt) 2010-05-03 2017-09-26 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
AU2012230899A1 (en) 2011-03-21 2013-10-10 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
CA2846083A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
JP6254087B2 (ja) 2011-10-15 2017-12-27 ジェネンテック， インコーポレイテッド 癌を治療するためのｓｃｄ１アンタゴニスト
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
MX2014010943A (es) 2012-03-16 2014-11-26 Genentech Inc Proteinas estabilizadas conformacionalmente de ingenieria.
MX2014010953A (es) 2012-03-16 2014-10-13 Hoffmann La Roche Metodos para tratamiento de melanoma con inhibidores pak1.
GB2517857A (en) 2012-04-25 2015-03-04 Biodesy Inc Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP3633377A1 (de) 2013-03-15 2020-04-08 F. Hoffmann-La Roche AG Biomarker und verfahren zur behandlung von pd-1 und pd-l1-verwandten leiden
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CA2944717A1 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
US10562946B2 (en) 2014-06-20 2020-02-18 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
JP6952605B2 (ja) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド 多特異性抗原結合タンパク質
WO2017196891A1 (en) 2016-05-09 2017-11-16 Biodesy, Inc. Methods and devices for detection of peripheral membrane protein interactions using nonlinear optical techniques
JP2019534858A (ja) 2016-09-09 2019-12-05 ジェネンテック， インコーポレイテッド Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
JP7397884B2 (ja) 2019-05-09 2023-12-13 ジェネンテック， インコーポレイテッド 抗体の作製方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527789A1 (de) * 1990-04-03 1993-02-24 Genentech, Inc. Hiv-hüllpolypeptide
AU9118891A (en) * 1990-11-29 1992-06-25 Smithkline Beecham Corporation Conformationally constrained peptides i
US6100377A (en) * 1994-06-10 2000-08-08 The Trustees Of The University Of Pennsylvania Constrained peptides

Also Published As

Publication number Publication date
EP0938497A1 (de) 1999-09-01
IL129772A0 (en) 2000-02-29
EP0938497B1 (de) 2007-02-28
DE69737415T2 (de) 2007-10-31
CA2270869A1 (en) 1998-05-14
ATE355300T1 (de) 2006-03-15
AU745101B2 (en) 2002-03-14
AU5428798A (en) 1998-05-29
WO1998020036A1 (en) 1998-05-14
JP2001503064A (ja) 2001-03-06

Similar Documents

Publication Publication Date Title
DE69737415D1 (de) Gespannte, helixformende peptide und verfahren um sie herzustellen
ES2147558T3 (es) Nuevos polipeptidos para promover la fijacion celular.
SG47062A1 (en) Synthetic antigens for the detection of antibodies to hepatitis virus
EP0484787A3 (en) Hcv-specific peptides, process for obtaining them and their use
EP0339504A3 (de) Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
CA2094027A1 (en) Osteogenic peptides
RU93045577A (ru) Слитные полипептиды
FR2669338B1 (de)
GB9307371D0 (en) Fusion proteins
DE69334328D1 (de) Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits
WO1992011370A3 (de) Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung
HUT44609A (en) Process for preparing new polypeptides
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
DK0426314T3 (da) HIV-relaterede peptider
EP0361956A3 (de) Expression von rekombinanten Proteinen mit niedrigem Molekulargewicht
ATE315646T1 (de) Leukocyten-aktivierender faktor
DE68925819D1 (de) Künstliche polypeptide und antikörper in zusammenhang mit epstein-barr-virus-nuklear-antigen
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee